BRPI0508048A - derivados de pirrol como inibidores do fator xa - Google Patents

derivados de pirrol como inibidores do fator xa

Info

Publication number
BRPI0508048A
BRPI0508048A BRPI0508048-7A BRPI0508048A BRPI0508048A BR PI0508048 A BRPI0508048 A BR PI0508048A BR PI0508048 A BRPI0508048 A BR PI0508048A BR PI0508048 A BRPI0508048 A BR PI0508048A
Authority
BR
Brazil
Prior art keywords
factor
compounds
formulas
factor viia
inhibitors
Prior art date
Application number
BRPI0508048-7A
Other languages
English (en)
Inventor
Armin Bauer
Michael Wagner
Marc Nazare
Volkmar Wehner
Matthias Urmann
Hans Matter
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0508048A publication Critical patent/BRPI0508048A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

DERIVADOS DE PIRROL COMO INIBIDORES DO FATOR Xa. A presente invenção refere-se à compostos das fórmulas (I) e (Ia), em que R¬0¬; R¬1¬; R¬2¬; R¬3¬; R¬4¬; R¬22¬, Q; V, G e M têm os significados indicados nas reivindicações. Os compostos das fórmulas I e Ia são compostos farmacologicamente ativos valiosos. Eles exibem um forte efeito anti-trombótico e são adequados para a terapia e profilaxia de distúrbios cardiovasculares tais como doenças trombo-embólicas ou restenoses. Eles são inibidores reversíveis das enzimas de coagulação sangüinea fator Xa (FXa) e/ou fator VIIa (FVIIa), e podem em geral ser aplicados em condições nas quais uma atividade indesejada de fator Xa e/ou fator VIIa está presente ou para a cura ou prevenção das quais uma inibição de fator Xa e/ou fator VIIa é pretendida. A invenção além disso refere-se à processos para a preparação de compostos das fórmulas (I) e (Ia), o emprego deles, em particular como ingredientes ativos em produtos farmacêuticos, e preparações farmacêuticas compreendendo-os.
BRPI0508048-7A 2004-02-27 2005-02-12 derivados de pirrol como inibidores do fator xa BRPI0508048A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04004503A EP1568698A1 (en) 2004-02-27 2004-02-27 Pyrrole-derivatives as factor Xa inhibitors
PCT/EP2005/001423 WO2005085239A2 (en) 2004-02-27 2005-02-12 PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS

Publications (1)

Publication Number Publication Date
BRPI0508048A true BRPI0508048A (pt) 2007-07-17

Family

ID=34745922

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0508048-7A BRPI0508048A (pt) 2004-02-27 2005-02-12 derivados de pirrol como inibidores do fator xa

Country Status (13)

Country Link
US (1) US7465806B2 (pt)
EP (2) EP1568698A1 (pt)
JP (1) JP4861306B2 (pt)
KR (1) KR20070000487A (pt)
CN (1) CN1926137A (pt)
AU (1) AU2005219507A1 (pt)
BR (1) BRPI0508048A (pt)
CA (1) CA2557270A1 (pt)
IL (1) IL177253A0 (pt)
PE (1) PE20051170A1 (pt)
TW (1) TW200538110A (pt)
UY (1) UY28778A1 (pt)
WO (1) WO2005085239A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
TW200840815A (en) * 2007-04-13 2008-10-16 Chang Chun Plastics Co Ltd Method for preparing melamine salt of bis(pentaerythritol phosphate)phosphoric acid
WO2008149382A1 (en) * 2007-06-08 2008-12-11 Advinus Therapeutics Private Limited Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
CN102639146A (zh) 2009-05-27 2012-08-15 耶达研究及发展有限公司 蛋白酶体抑制剂及其用途
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
PH12015501492B1 (en) 2013-01-08 2015-09-28 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
US11180484B2 (en) 2016-05-31 2021-11-23 Kalvista Pharmaceuticals Limited Pyrazole derivatives as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
RS63069B1 (sr) 2017-11-29 2022-04-29 Kalvista Pharmaceuticals Ltd Dozni oblici koji sadrže inhibitor kalikreina plazme
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
CN113192004B (zh) * 2021-04-01 2022-01-18 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） 一种基于冠脉多模影像裂纹形成和扩展的简化计算方法与斑块破裂风险量化的评估系统

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873607B (en) * 1986-06-13 1988-12-28 Warner Lambert Co N-1h-tetrazol-5-yl-2-thiophene carboxamides,n-1h-tetrazol-5-yl-2-pyrrole carboxamides n-1h-tetrazol-5-yl-2-furan carboxamides
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
CA2186497C (en) 1994-04-26 2008-06-17 Fahad Al-Obeidi Factor xa inhibitors
IT1282797B1 (it) * 1995-04-21 1998-03-31 Colla Paolo Pirril-(indolil)-aril-sulfoni e relativo processo di produzione ed impiego nella terapia delle infezioni da virus dell'aids
ATE443698T1 (de) * 1996-12-23 2009-10-15 Bristol Myers Squibb Pharma Co Stickstoffhaltige heterocyclen als faktor xa- hemmer
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6432947B1 (en) * 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
IL136637A0 (en) * 1997-12-22 2001-06-14 Du Pont Pharm Co Nitrogen containing heteroaromatics with ortho-substituted pi's as factor xa inhibitors
KR100608472B1 (ko) * 1997-12-24 2006-08-09 사노피-아벤티스 도이칠란트 게엠베하 인자 Ｘａ의 억제제로서의 인돌 유도체 및 이를 함유하는 약제학적 조성물
RU2202344C2 (ru) * 1998-03-26 2003-04-20 Джапан Тобакко Инк. Антагонисты ноцицептина, производные амида, аналгетик, способ инициирования антагонистического действия к ноцицептину, способ лечения боли, фармацевтические композиции
EP0987274A1 (en) 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
KR100659007B1 (ko) * 1999-02-10 2007-02-28 미츠비시 웰파마 가부시키가이샤 아미드 화합물 및 그 의약으로서의 용도
WO2001032628A1 (en) * 1999-11-03 2001-05-10 Bristol-Myers Squibb Pharma Company Cyano compounds as factor xa inhibitors
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
WO2002000651A2 (en) * 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
US7229780B2 (en) 2000-09-05 2007-06-12 The Medical Research Council Monoclonal antibody against ovarian carcinoma
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2002053157A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Thiazolidine derivative
WO2002053155A1 (en) * 2000-12-30 2002-07-11 Geron Corporation Telomerase inhibitor
AR035431A1 (es) * 2001-02-13 2004-05-26 Aventis Pharma Gmbh 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos
TWI243164B (en) * 2001-02-13 2005-11-11 Aventis Pharma Gmbh Acylated indanyl amines and their use as pharmaceuticals
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
EP1388341A1 (en) * 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
CA2496246A1 (en) * 2002-08-23 2004-03-04 Chiron Corporation Pyrrole based inhibitors of glycogen synthase kinase 3
WO2004039318A2 (en) * 2002-10-25 2004-05-13 Genesoft Pharmaceuticals, Inc. Anti-infective biaryl compounds
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
MXPA05007114A (es) * 2003-01-02 2005-08-26 Hoffmann La Roche Nuevos agonistas inversos del receptor cb1.
EP1479675A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7741341B2 (en) * 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors

Also Published As

Publication number Publication date
PE20051170A1 (es) 2006-02-07
EP1568698A1 (en) 2005-08-31
US20070049573A1 (en) 2007-03-01
EP1725550A2 (en) 2006-11-29
AU2005219507A1 (en) 2005-09-15
CA2557270A1 (en) 2005-09-15
TW200538110A (en) 2005-12-01
JP4861306B2 (ja) 2012-01-25
KR20070000487A (ko) 2007-01-02
CN1926137A (zh) 2007-03-07
WO2005085239A2 (en) 2005-09-15
JP2007523927A (ja) 2007-08-23
UY28778A1 (es) 2005-09-30
US7465806B2 (en) 2008-12-16
IL177253A0 (en) 2006-12-10
WO2005085239A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
BRPI0508048A (pt) derivados de pirrol como inibidores do fator xa
BR0214396A (pt) Indol-2-carboxamidas como inibidores de fator xa
BR0317659A (pt) Derivados de pirazol como inibidores de fator xa
BRPI0508320A (pt) derivados de beta-aminoácido como inibidores do fator xa
CL2004001074A1 (es) COMPUESTOS DERIVADOS DE INDOL, 2-AMIDO SUSTITUIDOS, INHIBIDORES DEL FACTO Xa, COMPOSICION FARMACEUTICA, PROCEDIMIENTO DE PREPARACION, UTILES PARA PREPARAR UN MEDICAMENTO PARA TRATAR INFARTO DE MIOCARDIO AGUDO, TRASTORNOS CARDIOVASCULARES, APOPLEJIA,
BR0116473A (pt) Derivados de oxibenzamidas como inibidores de fator xa
BRPI0410430A (pt) derivados de indazol como inibidores de fato xa
IL171843A (en) TRIAZOLE DERIVATIVES AS FACTOR Xa INHIBITORS
TNSN05297A1 (en) BENZIMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
YU29702A (sh) N-gvanidinoalkilamidi, njihovo dobijanje, njihova primena i farmaceutski preparati koji ih obuhvataju
BR0317003A (pt) Derivados de imidazol como inibidores do fator xa
TNSN05296A1 (en) AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS
TW200716620A (en) Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors
JO2467B1 (en) New indole derivatives as an inhibitor of Xa

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.